Invitrocue Chief Scientific Officer, Dr. Zahra Dantes, will be presenting our latest findings on our current validation study regarding breast cancer at ESMO Breast Cancer 2022, 3-5 May, in Berlin.
“Breast Cancer Organoids Mimic Disease Heterogeneity, Allow High-Throughput Drug Screening, and Show Correlation with Clinical Response” #202, Wednesday, 4 May, from 12:15 to 13:00 CEST.
Visit esmo.org to register your interest and access the virtual platform and live streaming of the session.
